Bugün FDA’ nın yaptığı açıklama sonrasında regeneron hisseleri işleme kapatıldı. Hedge Fund Winners in FDA Panel’s Regeneron Decision $REGN başlıklı yazımızdan detayları öğrenebilirsiniz. Yazının bir kısmını aktarıyorum:
A new eye medicine from Regeneron Pharmaceuticals (REGN) and Bayer AG was a safe and effective way of treating vision loss from macular degeneration, a U.S. advisory panel unanimously said on Friday.
The advisers to the Food and Drug Administration also said the drug, to be marketed as Eylea, could be dosed once every two months, giving it an edge over the typical monthly dosing of its chief competitor, Lucentis, from Roche Holding .
0 Yorum Var.:
Yorum Gönder